A Randomized, Double-Blind, Placebo-Controlled Study of Omalizumab for Idiopathic Anaphylaxis - Full Text View

Sponsor:	National Institute of Allergy and Infectious Diseases (NIAID)
Information provided by:	National Institutes of Health Clinical Center (CC)
ClinicalTrials.gov Identifier:	NCT00890162

Purpose

Background:

Omalizumab is an approved drug for the treatment of asthma by the Food and Drug Administration.
Researchers are now studying this drug in a double-blind placebo-controlled manner to assess efficacy in patients with idiopathic anaphylaxis (recurrent hypersensitive allergic episodes for which a cause is not identified).
The study will improve understanding of the mechanisms involved in anaphylactic reactions as a response to the downregulation (a decrease in the number of receptors on the surface of cells) in mast cell (a resident cell with several types of tissues) activation, and lead to the development of strategies to better prevent or treat anaphylaxis.

Objectives:

To determine whether treatment with omalizumab will reduce or prevent episodes of unprovoked anaphylaxis (an acute allergic reaction) in subjects with a history of idiopathic anaphylaxis.
To assess pharmacodynamics (physiological effects of a drug) and identify patients with undiagnosed mastocytosis (rare disorders caused by too many mast cells).
To investigate cellular and molecular mechanisms of signaling and the effect of omalizumab on mast cells or basophils (a cell in the leukocyte family that releases histamine, which affects allergic response) and explore other regulatory pathways that may be involved with modulation of mast cell degranulation.

Eligibility:

Patients between 18 and 60 years of age who have been diagnosed with idiopathic anaphylaxis, a diagnosis that is made only after other causes of anaphylaxis have been considered.
Patients with documented anaphylaxis episodes (mild to severe) at least six times per year, at least once within the last 2 months, and one episode per quarter with at least one of the following:
- Elevated serum tryptase above baseline within 2 hours of the event.
- Emergency room visit with documented anaphylaxis without a known cause established by the acute onset of an illness (minutes to several hours) with involvement of the skin, mucosal tissue, or both (generalized hives, itching or flushing, swollen lips-tongue-throat) and at least one of the following: (1) respiratory compromise or gastrointestinal involvement (shortness of breath, wheeze-bronchospasm, throat tightness, low oxygen levels, nausea, vomiting, or abdominal pain); or (2) reduced blood pressure or associated symptoms of end-organ dysfunction (collapse, loss of consciousness, or loss of bladder or bowel control).
- Hospitalization for anaphylaxis.
Patients must provide a letter of referral, with copies of pertinent medical history and laboratory tests, from the prospective participant's local physician, and have the ability to give informed consent.
Women with childbearing potential must have a negative pregnancy test, and must agree to practice abstinence or effective birth control from the start of the protocol and for 3 months following the last injection of the study drug.

Design:

Participants will undergo a clinical evaluation, blood tests, and a bone marrow biopsy and aspirate.
Participants will be randomized to either drug or placebo and will receive two doses of omalizumab or a matched placebo while hospitalized, followed by continued outpatient therapy, every 2 to 4 weeks, for up to 12 months.
Participants will remain on the assigned regimen for 6 months or until they have experienced two anaphylactic events within 4 months that may be possibly related to the study drug, whichever comes first. At that time, the participant will be discontinued from drug administration.

Condition	Intervention	Phase
Anaphylaxis Hypotension Bronchospasm Angioedema	Drug: Epinephrine Procedure: Bone Marrow Apsiration Drug: Omalizumab (Xolair)	Phase II

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study
Official Title:	A Randomized Double-Blinded, Placebo-Controlled Study of Omalizumab for Idiopathic Anaphylaxis

Resource links provided by NLM:

MedlinePlus related topics: Allergy Low Blood Pressure

Drug Information available for: Epinephrine bitartrate Epinephrine Omalizumab

U.S. FDA Resources

Further study details as provided by National Institutes of Health Clinical Center (CC):

Primary Outcome Measures:

The primary objective of this study is to determine if treatment with omalizumab over 6 months will produce a reduction in the number and timing of anaphylactic events in subjects with a history of frequent idiopathic anaphylaxis. [ Designated as safety issue: Yes ]

Secondary Outcome Measures:

Assess the pharmacodynamics of omalizumab in subjects with anaphylaxis. Examine the effects of omalizumab in the immunopathogenesis of anaphylaxis. Identify subjects with the D816V mutation. [ Designated as safety issue: Yes ]

Estimated Enrollment:	30
Study Start Date:	April 2009
Estimated Study Completion Date:	January 2011
Estimated Primary Completion Date:	January 2011 (Final data collection date for primary outcome measure)

Intervention Details:

N/A

Detailed Description:

Anaphylaxis is a severe systemic reaction caused by release of mediators from mast cells and basophils. Manifestations include cutaneous, respiratory, cardiovascular, or gastrointestinal signs and symptoms. Although anaphylaxis is frequently attributed to exposure to specific foods, drugs, and insect venoms in sensitive individuals, a causative factor is not identified in 30% to 50% of patients with recurrent anaphylactic episodes (idiopathic anaphylaxis).

Currently, therapeutic options for the treatment of idiopathic anaphylaxis are limited with variable efficacy. This pilot study will examine the hypothesis that omalizumab (Xolair(Registered Trademark)) will decrease episodes of unexplained anaphylaxis in patients with idiopathic anaphylaxis. Omalizumab is approved for use in asthma. We will examine the safety profile and efficacy of omalizumab in patients with anaphylaxis. In addition, the study will investigate whether patients with anaphylaxis have unique molecular and cellular defects in mast cells that result in these cells being more susceptible to degranulation.

The study will enroll patients with idiopathic anaphylaxis. Patients will undergo a clinical evaluation, blood tests, and a bone marrow biopsy and aspirate. Patients will be randomized to either drug or placebo and will receive, in a double-blind placebo-controlled approach, 2 doses of omalizumab or a matched placebo while hospitalized, followed by continued outpatient therapy, every 2 to 4 weeks, for up to 12 months. Patients will remain on the assigned regimen until they have experienced 2 anaphylactic events (post 24-hr window) determined to be unrelated to study drug or have been followed for 6 months, whichever comes first. After this point, the patient will be discontinued from drug administration until unblinding. This design ensures that no patient will have more than 2 anaphylactic episodes while on placebo. Research studies will be conducted to elucidate other markers or pathways of mast cell regulation.

The primary outcome will be a reduction in the number and timing of anaphylactic events during the randomized phase. Secondary outcomes will include a reduction in surface IgE receptors on basophils, identification of mutations in c-kit, and evaluation of the efficacy of omalizumab on other mediator-induced symptoms associated with anaphylaxis. The study will improve the understanding of the mechanisms involved in anaphylactic reactions as a response to the downregulation of mechanisms involved in mast cell activation that could, in turn, lead to development of strategies to better prevent or treat anaphylaxis.

Eligibility

Ages Eligible for Study:	18 Years to 60 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

INCLUSION CRITERIA:

Subject must be at least 18 years of age and no older than 60 years of age.

Diagnosis of idiopathic anaphylaxis, a diagnosis of exclusion, assigned after other causes of anaphylaxis and other diseases in the differential diagnoses have been considered.

Documented anaphylaxis (mild-severe) at least 6 times per year, at least 1 within the last 2 months, and 1 episode per quarter with 1 of the following:

Elevated serum tryptase above baseline within 2 hours of the event.
Emergency room visit with documented anaphylaxis without an etiology established by the acute onset of an illness (minutes to several hours) with involvement of the skin, mucosal tissue, or both (e.g., generalized hives, pruritus or flushing, swollen lips-tongue-uvula) [Grade 1]* and at least 1 of the following:
1. Respiratory compromise or gastrointestinal involvement (e.g., dyspnea, wheeze-bronchospasm, stridor, reduced peak expiratory flow, hypoxemia, nausea, vomiting, or abdominal pain [Grade 2]*).
2. Reduced blood pressure or associated symptoms of end-organ dysfunction (e.g., hypotonia [collapse], syncope, or incontinence [Grade 3]*).
Hospitalization for anaphylaxis: hospital records with documented anaphylaxis without known cause established by the acute onset of an illness (minutes to several hours) with involvement of the skin, mucosal tissue, or both (e.g., generalized hives, pruritus or flushing, swollen lips-tongue-uvula) [Grade 1]*) and at least one of the following:
1. Respiratory compromise or gastrointestinal involvement (e.g., dyspnea, wheeze-bronchospasm, stridor, reduced peak expiratory flow, hypoxemia, nausea, vomiting, or abdominal pain [Grade 2]*).
2. Reduced blood pressure or associated symptoms of end-organ dysfunction (e.g., hypotonia [collapse], syncope, or incontinence [Grade 3]*).
Letter of referral, with copies of pertinent medical history and laboratory tests, from prospective study participant's local physician.
Ability to give informed consent.
Women of childbearing potential must have a negative beta-HCG serum or urine pregnancy test prior to each injection, and must agree to practice abstinence or effective contraception from initiation of the protocol and for 3 months following the last infusion of the study drug (effective contraception methods include abstinence; surgical sterilization of either partner, barrier methods such as diaphragm, condom, cap, or sponge; or hormonal contraception).
- Severity grading of anaphylaxis

EXCLUSION CRITERIA:

A volunteer who satisfies any of the following exclusion criteria will be ineligible to participate in this study.

Presence of conditions which, in the judgment of the investigator or the referring physician, may put the subject at undue risk for study participation or travel (such as an acute infection, severe thrombocytopenia, coronary artery disease, uncontrolled hypertension, congestive heart failure, chronic beta blocker therapy such as atenolol or metoprolol, or myeloproliferative disease).
History of malignancy
Known cause for anaphylaxis or flushing
Diagnosis of mastocytosis
Inability to provide informed consent
Inability or refusal to undergo a bone marrow biopsy and aspirate
HIV positive or other known immunodeficiency
Active or chronic hepatitis
Use of any other investigational agent within 30 days of the study
Current use of corticosteroids or other immunosuppressant medications
Pregnant or nursing women
Positive pregnancy urine test
IgE levels and subject's weight that cause dosing to be above standard dosing guidelines in the current Package Insert.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00890162

Contacts

Contact: Patient Recruitment and Public Liaison Office	(800) 411-1222	prpl@mail.cc.nih.gov
Contact: TTY	1-866-411-1010

Locations

United States, Maryland
National Institutes of Health Clinical Center, 9000 Rockville Pike	Recruiting
Bethesda, Maryland, United States, 20892

Sponsors and Collaborators

National Institute of Allergy and Infectious Diseases (NIAID)

More Information

Additional Information:

NIH Clinical Center Detailed Web Page This link exits the ClinicalTrials.gov site

Publications:

Thong BY, Cheng YK, Leong KP, Tang CY, Chng HH. Anaphylaxis in adults referred to a clinical immunology/allergy centre in Singapore. Singapore Med J. 2005 Oct;46(10):529-34.

Webb LM, Lieberman P. Anaphylaxis: a review of 601 cases. Ann Allergy Asthma Immunol. 2006 Jul;97(1):39-43. Review.

Neugut AI, Ghatak AT, Miller RL. Anaphylaxis in the United States: an investigation into its epidemiology. Arch Intern Med. 2001 Jan 8;161(1):15-21. Review.

Responsible Party:	National Institutes of Health ( Melody C. Carter, M.D./National Institute of Allergy and Infectious Diseases )
Study ID Numbers:	090129, 09-I-0129
Study First Received:	April 28, 2009
Last Updated:	January 29, 2010
ClinicalTrials.gov Identifier:	NCT00890162 History of Changes
Health Authority:	United States: Federal Government

Keywords provided by National Institutes of Health Clinical Center (CC):

Omalizumab
Idiopathic Anaphylaxis
Serum Tryptase
Placebo-Controlled

Adult
Anaphylaxis
Allergic Reaction

Additional relevant MeSH terms:

Hypotension
Respiratory System Agents
Neurotransmitter Agents
Bronchial Spasm
Molecular Mechanisms of Pharmacological Action
Adrenergic Agents
Bronchial Diseases
Anaphylaxis
Physiological Effects of Drugs
Adrenergic Agonists
Hypersensitivity
Respiratory Tract Diseases
Therapeutic Uses
Vasoconstrictor Agents
Cardiovascular Diseases

Epinephrine
Omalizumab
Skin Diseases, Vascular
Adrenergic alpha-Agonists
Adrenergic beta-Agonists
Skin Diseases
Immune System Diseases
Angioedema
Sympathomimetics
Vascular Diseases
Anti-Asthmatic Agents
Urticaria
Anti-Allergic Agents
Cardiovascular Agents
Pharmacologic Actions

ClinicalTrials.gov processed this record on February 08, 2010